SUNNYVALE, Calif., July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKnife® platform in the treatment of neurological indications with non-invasive radiosurgery. The data highlight the benefits experienced by neurosurgeons for more than two decades, including the ability to effectively and efficiently deliver radiation in single and multi-fraction sessions, treat benign and functional cases, primary brain and spine tumors and metastases, as well as previously irradiated tumors.
"We are proud to see the impact that CyberKnife technology has on advancing patient care, with nearly 50 abstracts presented at the ISRS conference showcasing the system's use for non-invasive radiosurgery treatments. The data indicate we are fulfilling our goal to offer clinicians the tools they need to enhance the quality of care they offer and provide additional treatment options to their patients," said Suzanne Winter, president and chief executive officer of Accuray.
Ms. Winter continued, "The CyberKnife platform continues to evolve with powerful enhancements that enable clinicians to continue delivering extremely precise and accurate radiosurgery treatments, while also significantly reducing treatment times, providing a more comfortable experience for patients and enabling medical care teams to treat more patients each day. But we are not stopping here. Through investments in research and development and industry partnerships we will continue to introduce best-in-class innovations that make an incredible system even better."
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
New CyberKnife System Data: Helping to Make a Clinical Difference for Patients in as little as 1 to 5 Treatments
The CyberKnife System delivers frameless radiosurgery treatments, unlike other systems that use a fixed metal frame attached to the patient's head to prevent movement during treatment. It provides clinical teams with a device that maximizes patient comfort and can deliver precision treatments in a single session, as well as up to 5 ultra-hypofractionated treatments, expanding access to radiosurgery to more patients. Studies shared at the ISRS meeting indicate radiosurgery delivered with the CyberKnife System can:
Provide excellent local control with very low toxicity when treating perioptic meningiomas, tumors that are challenging to treat because of their close proximity to critical brain structures impacting a person's vision1